ArticleFrontiers in medicine2026
Monomorphic epitheliotropic intestinal T-cell lymphoma presenting as acute small intestinal perforation: a case report and exploratory BCL-2-targeted therapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report a rare case of monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) presenting with acute gastrointestinal perforation and to describe the use of an exploratory regimen combining a BCL-2 inhibitor (Venetoclax) with CHOP chemotherapy, highlighting the diagnostic challenges and therapeutic considerations for this aggressive disease. Methods: We detail the clinicopathological journey of a 72-year-old male patient who presented with an acute abdomen. The diagnosis was established through surgical pathology and comprehensive immunohistochemistry. Following an initial treatment refusal and a subsequent disease recurrence manifesting as a second perforation, the patient received Venetoclax combined with CHOP. The relevant literature was reviewed to inform the diagnostic and therapeutic decisions. Results: Emergency surgery for perforation revealed MEITL (initially staged as Lugano stage I). The patient initially declined therapy but presented 9 months later with recurrent perforation, confirmed as disease relapse via pathology. Immunohistochemistry showed tumor cells were CD3 (weakly positive), CD8+, CD56+, Bcl-2 (3+), and Ki-67 (~60%). Postoperative PET/CT revealed limited retroperitoneal lymph node involvement. The patient received four cycles of Venetoclax (200 mg/day, days 1-14) plus CHOP, achieving complete metabolic remission on follow-up PET/CT without significant myelosuppression. The 9-month untreated interval despite high Ki-67 is noteworthy. Conclusion: MEITL is a highly aggressive lymphoma often presenting as a surgical emergency. Diagnosis relies on histopathology and a characteristic immunophenotype (CD3+ CD8+ CD56+). This case suggests that incorporating BCL-2 inhibition into the treatment of Bcl-2-high MEITL may represent a biologically rational strategy. Besides, the prolonged untreated interval observed in this patient highlights the potential biological heterogeneity of MEITL. While the observed complete metabolic remission is encouraging, this finding remains hypothesis-generating and requires validation in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.